- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 180064-38-4] Minodronicacid
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-16322 |
| Brand: | MCE |
| CAS: | 180064-38-4 |
Overview
| MDL | MFCD00890772 |
|---|---|
| Molecular Weight | 322.15 |
| Molecular Formula | C9H12N2O7P2 |
| SMILES | OC(P(O)(O)=O)(P(O)(O)=O)CC1=CN=C2C=CC=CN21 |
Summary
IC50 & Target
P2X2/3 [2]
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00965978 | Astellas Pharma Inc|Ono Pharma USA Inc |
Osteoporosis|Osteoporosis, Postmenopausal|Bone Diseases
|
July 2009 | Phase 1 |
| NCT00212628 | Ono Pharmaceutical Co. Ltd|Astellas Pharma Inc |
Involutional Osteoporosis
|
June 2004 | Phase 3 |
| NCT00794443 | Astellas Pharma Inc|Ono Pharmaceutical Co. Ltd |
Osteoporosis|Bone Loss, Age-Related
|
November 2008 | Phase 2|Phase 3 |
| NCT02295436 | Wuhan Union Hospital, China |
Osteoporosis
|
August 2014 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
H 2 O : 5 mg/mL ( 15.52 mM ; Need ultrasonic and warming)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.1041 mL | 15.5207 mL | 31.0414 mL |
| 5 mM | 0.6208 mL | 3.1041 mL | 6.2083 mL |
| 10 mM | 0.3104 mL | 1.5521 mL | 3.1041 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 2 mg/mL (6.21 mM); Clear solution; Need ultrasonic
References
- [1] Sato K, et al. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer. 2006 Nov 20;95(10):1354-61.
- [2] Tanaka M, et al. Minodronic acid induces morphological changes in osteoclasts at bone resorption sites and reaches a level required for antagonism of purinergic P2X2/3 receptors. J Bone Miner Metab. 2018 Jan;36(1):54-63.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.